Newsroom
Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Corporate Sustainability
  • Careers
Company Announcement
03 June 2026

Main Results of 2026 Annual and Extraordinary General Meeting

The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg.  All of the draft resolutions...
Company Announcement
02 June 2026

Alvotech to present at upcoming investor conferences in June

REYKJAVIK, ICELAND (June 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...
Company Announcement
01 June 2026

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

REYKJAVIK, ICELAND (June 1, 2026) — Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making agreement. According to the agreement, Islandsbanki places bids and...
Company Announcement
11 May 2026

Alvotech announces completion of FDA surveillance inspection at Reykjavik facility

Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, ICELAND – May 11, 2026 – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the...
Financial Reports
06 May 2026

Alvotech Q1 2026 Financial Results

Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights  A supplemental long‑form earnings release providing additional operational details and business update for Q1...
Company Announcement
30 April 2026

Alvotech Announces a Change in its Executive Team

REYKJAVIK, ICELAND (April 30, 2026) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
Company Announcement
24 April 2026

Alvotech to Report Financial Results for the First Quarter of 2026

REYKJAVIK, ICELAND (April 24, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...
Company Announcement
01 April 2026

Transactions of Managers and Closely Associated Persons

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding a transaction of managers and closely associated persons, announcing the vesting of an equity incentive award granted to the Chief Executive Officer of Alvotech
Managers’ Transactions
01 April 2026

Transactions of Managers and Closely Associated Persons

Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP ehf. announced the acquisition of 318,000 shares in Alvotech on March 31, 2026, from Robert Wessman, Executive Chairman of Alvotech and Chairman and principal owner of Aztiq group. ATP ehf. belongs to the Aztiq group and the transaction was an intra-group transaction. The transaction price was USD 3.29 per share.
Financial Reports
30 March 2026

Alvotech files Annual Report with the SEC

REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission...
1234…32
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.